Evidence map›Paper›PMID 34802281›Full record

ArticleJournal of diabetes science and technology2023

How Frequently and for How Long Do Adults With Type 2 Diabetes Use Management Apps? The REALL Study.

Lawrence Fisher, Addie L Fortmann, Caterina Florissi, Keaton Stoner, Jennifer Knaebel, Andreas Stuhr

Open access · greenAbstract read
In one paragraph

Article in Journal of diabetes science and technology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.5field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 2 countries.

Lawrence FisherDepartment of Family and Community Medicine, University of California, San Francisco, San Francisco, CA, USA.ORCID 0000-0001-9481-9727
Addie L FortmannScripps Whittier Diabetes Institute, Scripps Health, San Diego, CA, USA.
Caterina FlorissidQ&A-The Diabetes Research Company, San Francisco, CA, USA.
Keaton StonerdQ&A-The Diabetes Research Company, San Francisco, CA, USA.
Jennifer KnaebelAscensia Diabetes Care, Parsippany, NJ, USA.
Andreas StuhrAscensia Diabetes Care, Parsippany, NJ, USA.
Diabetes Australia · AUDiabetes Care Center · USScripps Health · USUniversity of California, San Francisco · US

Funding

New York Regional Center for Diabetes Translation Research - Translational Intervention Methodology CoreP30DK111022 · NIDDK · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI JEFFREY GONZALEZ · 2016 to 2026
$7.8M
NIDDK NIH HHS P30 DK111022
6 · The paper itself

Abstract

objectiveThe objective of the study is to identify predictors of utilization of a type 2 diabetes (T2D) management App over time for insulin users (IUs) and noninsulin users (NIUs). RESEARCH DESIGN AND

methodsWe followed over 16 weeks a national sample of unselected T2D adults who independently elected to download and pair a CONTOUR DIABETES App with their CONTOUR NEXT ONE glucose meter. App use and frequency of glucose testing were recorded. Baseline surveys recorded participant demographic, disease status, distress, medication taking, and views of technology to predict utilization.

resultsMean age was 51.6 years (108 IUs; 353 NIUs), 48% were female, time with diabetes was 6.9 years, and self-reported HbA1c was 8.1% (36.3 mmol/mol). Mean duration of App use was 85.4 days and 40% stopped using the App before 16 weeks. Continuous users were older and reported higher distress, better medication taking, and more positive attitudes toward technology (all

conclusionsApp use and testing decreased markedly over time. Variations in the predictors of frequency of App use suggest that the utilization of mobile technologies requires a tailored approach that addresses the specific needs of individual users, compared with adopting a one-size-fits-all strategy, and that IUs and NIUs may require very different strategies of customization.

Indexed as

Diabetes Mellitus, Type 2Mobile ApplicationsAdultFemaleGlucoseGlycated HemoglobinHumansInsulinMaleMiddle AgedGlucoseGlycated HemoglobinInsulinApp frequencyApp usediabetes managementlongitudinal assessmenttype 2 diabetes

Identifiers

PMID34802281
PMCPMC10012363
OpenAlexW3217066939

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.